FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
notruction 1/h)	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per response	: 0.5									

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

.(0). 0	ee msuucuon																		
Name and Address of Reporting Person* Cohen Joshua B					2. Issuer Name and Ticker or Trading Symbol Amylyx Pharmaceuticals, Inc. [AMLX]								5. Relationship of Reporting Person(s) to Iss (Check all applicable) Director 10% Ow					wner	
(Last) (First) (Middle) C/O AMYLYX PHARMACEUTICALS, INC. 43 THORNDIKE STREET					3. Date of Earliest Transaction (Month/Day/Year) 09/30/2024								Officer (give title Other (specify below) below) Co-Chief Executive Officer						
(Street) CAMBR (City)	CAMBRIDGE MA 02141						4. If Amendment, Date of Original Filed (Month/Day/Year)							. Indivine)					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			ear) Execution		cution Date, ny		3. Transaction Code (Instr. 8) 4. Securities Acc Disposed Of (D)			Acquire D) (Inst	d (A) or r. 3, 4 and	and 5) S		5. Amount of Securities Beneficially Owned Following Reported		Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v .	Amount	(A) or (D)	Price	, т		ansaction(s) str. 3 and 4)			(111501.4)	
Common Stock 09/30/202				24				S ⁽¹⁾		18,589(1)	D	\$3.196	3,220,569		20,569]	D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Exed if an	Deemed cution Date, ry nth/Day/Year)		action (Instr.			Exp (Mo	Date Exer Diration E Donth/Day		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Der	Price of ivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y O D OI (I)	0. Dwnership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownershi (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	e ercisable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$3.12 to \$3.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

/s/ Joshua B. Cohen

10/02/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.